Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Butrans

(Injectable subcutaneous buprenorphine)

Small molecule

0

Indications

1

Total Trials

1

Active Trials

0

Competitors

7

FDA Applications

NDA/BLA/ANDA regulatory filings

Timeline

Expected Milestones

Q2 2029

ApprovedRecruiting

Opioid Use Disorder

NCT04375033

Clinical

Trials by Indication[1]

Opioid Use Disorder1 trial

CSP #2014 - Comparative Effectiveness of Two Formulations of Buprenorphine for Treating Opioid Use Disorder in Veterans (VA-BRAVE)

Recruiting·VVA Office of Research and Development·Approved·NCT04375033·952 enrolled

Regulatory

FDA Approval Timeline[3]

Jan 1, 1982

BUPRENEX

NDA NDA018401

Oct 8, 2002

SUBUTEX

NDA NDA020732

Jun 30, 2010

BUTRANS

NDA NDA021306

Oct 23, 2015

BELBUCA

NDA NDA207932

May 26, 2016

PROBUPHINE

NDA NDA204442

Nov 30, 2017

SUBLOCADE

NDA NDA209819

May 23, 2023

BRIXADI

NDA NDA210136

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Injectable subcutaneous buprenorphine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Injectable subcutaneous buprenorphine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA210136). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Indivior Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: IIndivior Inc.

Related News